Obiltoxaximab Uses, Dosage, Side Effects and more
Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
| Trade Name | Obiltoxaximab |
| Generic | Obiltoxaximab |
| Obiltoxaximab Other Names | Obiltoxaximab |
| Type | Intravenous |
| Weight | 148000.0 Da |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Obiltoxaximab is a monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.
Obiltoxaximab is also used to associated treatment for these conditions: Inhaled anthrax caused by Bacillus anthracis
How Obiltoxaximab works
ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.
